Literature DB >> 22079074

International collaborative proficiency study of Human Papillomavirus type 16 serology.

Carina Eklund1, Elizabeth R Unger, Denise Nardelli-Haefliger, Tiequn Zhou, Joakim Dillner.   

Abstract

We performed an international proficiency study of Human Papillomavirus (HPV) type 16 serology. A common methodology for serology based on virus-like particle (VLP) ELISA was used by 10 laboratories in 6 continents. The laboratories used the same VLP reference reagent, which was selected as the most stable, sensitive and specific VLP preparation out of VLPs donated from 5 different sources. A blinded proficiency panel consisting of 52 serum samples from women with PCR-verified HPV 16-infection, 11 control serum samples from virginal women and the WHO HPV 16 International Standard (IS) serum were distributed. The mean plus 3 standard deviations of the negative control serum samples was the most generally useful "cut-off" criterion for distinguishing positive and negative samples. Using sensitivity of at least 50% and a specificity of 100% as proficiency criteria, 6/10 laboratories were proficient. In conclusion, an international Standard Operating Procedure for HPV serology, an international reporting system in International Units (IU) and a common "cut-off" criterion have been evaluated in an international HPV serology proficiency study.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079074     DOI: 10.1016/j.vaccine.2011.10.096

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.

Authors:  Ali Rowhani-Rahbar; Frances B Alvarez; Janine T Bryan; James P Hughes; Stephen E Hawes; Noel S Weiss; Laura A Koutsky
Journal:  J Clin Virol       Date:  2011-12-30       Impact factor: 3.168

Review 2.  Opportunities and challenges for human papillomavirus vaccination in cancer.

Authors:  Richard B S Roden; Peter L Stern
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

Review 3.  Long-term efficacy and safety of human papillomavirus vaccination.

Authors:  Rosa De Vincenzo; Carmine Conte; Caterina Ricci; Giovanni Scambia; Giovanni Capelli
Journal:  Int J Womens Health       Date:  2014-12-03

4.  Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.

Authors:  Ligia A Pinto; Joakim Dillner; Simon Beddows; Elizabeth R Unger
Journal:  Vaccine       Date:  2018-02-01       Impact factor: 3.641

5.  Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

Authors:  Ralph-Sydney Mboumba Bouassa; Hélène Péré; Camélia Gubavu; Thierry Prazuck; Mohammad-Ali Jenabian; David Veyer; Jean-François Meye; Antoine Touzé; Laurent Bélec
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

6.  Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study.

Authors:  Fangfang Liu; Qiuju Deng; Chanyuan Zhang; Yaqi Pan; Ying Liu; Zhonghu He; Min Sun; Mengfei Liu; Jingjing Li; Xiang Li; Chaoting Zhang; Dong Hang; Tao Ning; Chuanhai Guo; Yongmei Liang; Ruiping Xu; Lixin Zhang; Hong Cai; Yang Ke
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

7.  Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico &in-vivo insight to vaccine development.

Authors:  Anoop Kumar; Showket Hussain; Gagan Sharma; Ravi Mehrotra; Lutz Gissmann; Bhudev C Das; Mausumi Bharadwaj
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.